This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.
$250.00 -
This issue profiles a novel microchip-enabled drug-delivery system, a technology for reducing diesel engine emissions, and head-up displays that get transformed into consumer wearables.
$250.00 -
This issue profiles miotoxicity and drug screening assays through micropatterning techniques, leveraging glycobioengineering for cancer research, and pharmacological chaperones to enhance enzyme replacement therapies.
$950.00 -
This issue profiles a biomarker for detection of mental disorders in women, a novel gene-control molecule that targets chronic wounds, and gene therapy for treatment of Parkinson’s disease.
$250.00 -
29 Jun 2015 | Global | Technology Research
Trends in mammalian cell cultures
Technology Market Penetration and Roadmapping
With the growing need for better therapeutics, and the current patent cliff that is underway, therapies such as monoclonal antibodies, recombinant protein therapeutics and even vaccines for a whole host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics...
$4,950.00 -
This issue profiles a novel indicator for breast cancer screening, a next generation behavioral health platform, and a diagnostic and therapeutic PET imaging agent
$950.00 -
26 Jun 2015 | Global | Technology Alert
Genetic Technology Alert. Sound Wave-Based Point of Care Diagnostic Device for Biomarker Detection; Novel Methodology to Detect Antiviral Antibody Interactions
This issue profiles a sound wave-based point of care diagnostic device for biomarker detection, a novel methodology to detect antiviral antibody interactions, and placenta-on-a-chip technology for understanding placental function
$250.00 -
This issue profiles an injectable drug eluting bone substitute for bone healing and remodelling, an innovative image acquisition platform that boosts medical sonography capabilities, and a drug-eluting biodegradable scaffold for percutaneous coronary intervention.
$950.00 -
This issue profiles 3D bioprinting for breast cancer reconstruction of nipple areola complex, enablement of cardiovascular tissue using extracellular matrix-based technology, and a experimental technique for development of whole organs
$250.00 -
This issue profiles a submental contouring injectable drug that has been approved by FDFA, treatment for irritable bowel syndrome that has obtained FDA approval, and a strategic procedure to prepare more reliable antibody drug conjugates.
$950.00
